drugset / Trial / NCT03894540
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).
Timeline
- Start
- 2019-03-22
- Primary completion
- 2020-12-21
- Completion
- 2020-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPN60090 | Small molecule | — | Oral |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |